IMA (ImageneBio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IMA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Yanina Grant-Huerta | Chief Financial Officer | A | — | — |
| 2026-08-17 | Kristin Yarema | Chief Executive Officer | A | — | — |
| 2026-07-28 | Kristin Yarema | Chief Executive Officer | MIXED | — | — |
| 2026-07-20 | Robert B Lally | Principal Accounting Officer | Sell | — | — |
| 2026-06-18 | JOSEPH P SLATTERY | Director | A | — | — |
| 2026-06-18 | Otello Stampacchia | Director | A | — | — |
| 2026-06-18 | David P Bonita | Director | A | — | — |
| 2026-06-18 | Jonathan Jian Wang | Director | A | — | — |
| 2026-04-16 | OrbiMed Genesis GP LLC | Director | Buy | — | — |
| 2026-04-16 | David P Bonita | Director | Buy | — | — |
| 2026-03-18 | Kristin Yarema | Chief Executive Officer | A | — | — |
| 2026-01-02 | Erin Butler | Principal Accounting Officer | A | — | — |
| 2025-12-29 | JOSEPH P SLATTERY | Director | Buy | — | — |
| 2025-12-22 | JOSEPH P SLATTERY | Director | A | — | — |
| 2025-12-22 | Stephen Hui Wang | Director | A | — | — |
| 2025-12-22 | Jonathan Jian Wang | Director | A | — | — |
| 2025-10-10 | Stephen Hui Wang | Director | A | — | — |
| 2025-08-15 | Jonathan Jian Wang | Director | A | — | — |
| 2025-08-07 | Yufang Lu | Chief Medical Officer | A | — | — |
| 2025-07-30 | Otello Stampacchia | Director | MIXED | — | — |
| 2025-07-30 | David P Bonita | Director | MIXED | — | — |
| 2025-07-30 | Kristin Yarema | Chief Executive Officer | A | — | — |
| 2025-07-30 | OrbiMed Genesis GP LLC | Director | A | — | — |
| 2025-07-29 | Erin Butler | Principal Accounting Officer | A | — | — |
| 2025-07-29 | Jotin Marango | Chief Financial Officer | MIXED | — | — |
| 2010-07-02 | Gordon Norman | Chief Innovation Officer | M | — | — |
| 2010-07-02 | Thomas Underwood | CEO, Alere Health LLC | M | — | — |
| 2010-06-21 | Emanuel Hart | VP, Lat. Am., Africa & Russia | MIXED | — | — |
| 2010-06-08 | JOHN F LEVY | Director | M | — | — |
| 2010-05-19 | PAUL T HEMPEL | Sr VP, LD & Legal Affairs | MIXED | — | — |
| 2010-03-02 | DAVID SCOTT | Chief Technical Officer | A | — | — |
| 2010-03-02 | JEROME F MCALEER | VP, Research & Development | A | — | — |
| 2010-03-02 | RON ZWANZIGER | Chairman, CEO & President | A | — | — |
| 2010-02-23 | PETER TOWNSEND | Director | MIXED | — | — |
| 2010-01-05 | DAVID SCOTT | Chief Technical Officer | A | — | — |
| 2010-01-05 | JEROME F MCALEER | VP, Research & Development | A | — | — |
| 2010-01-05 | RON ZWANZIGER | Chairman, CEO & President | A | — | — |
| 2009-11-02 | Ellen Chiniara | General Counsel and Asst. Sec. | M | — | — |
| 2009-11-02 | Emanuel Hart | VP, Lat. Am., Africa & Russia | M | — | — |
| 2009-11-02 | Dave Teitel | Chief Financial Officer | M | — | — |
| 2009-11-02 | Jon Russell | VP, Finance | M | — | — |
| 2009-09-10 | PAUL T HEMPEL | Sr VP, LD & Legal Affairs | M | — | — |
| 2009-09-10 | JOHN F LEVY | Director | M | — | — |
| 2009-07-02 | Ellen Chiniara | General Counsel and Asst. Sec. | M | — | — |
| 2009-07-02 | HILDE EYLENBOSCH | President,Consumer Diagnostics | M | — | — |
| 2009-07-02 | PAUL T HEMPEL | Sr VP, LD & Legal Affairs | M | — | — |
| 2009-07-02 | JOHN YONKIN | President, North America | M | — | — |
| 2009-07-02 | Jon Russell | VP, Finance | M | — | — |
| 2009-07-02 | Ronald D Geraty | CEO, Alere Medical, Inc. | M | — | — |
| 2009-07-02 | MICHAEL K BRESSON | VP, Mergers and Acquisitions | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,115,005 | — |
| — | Director | 753,441 | — |
| — | Director | 753,062 | — |
| — | Chief Executive Officer | 493,705 | — |
| — | Director | 455,361 | — |
| — | Chief Financial Officer | 65,000 | — |
| — | Principal Accounting Officer | 55,582 | — |
| — | Principal Accounting Officer | 25,551 | — |
| — | Director | 16,000 | — |
| — | Director | 12,535 | — |
| — | Chief Financial Officer | 11,146 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMA quote page; the site-wide leaderboard is on the insider transactions hub.